https://pittplusme.org/study/intrepid
The INTREPID HS Study- adults 18 and older
STUDY BASICS
Do you have hidradenitis suppurativa (HS)? You may be eligible for a research study to assess the safety and efficacy of lutikizumab compared with placebo for the treatment of signs and symptoms of moderate to severe HS. Compensation is provided.
STUDY PURPOSE
The INTREPID HS Study is a year-long clinical research study designed to evaluate the safety and efficacy of an investigational drug compared to a placebo (something that looks like the investigational drug but has no effect on the body) in reducing symptoms and improving the quality of life for participants living with hidradenitis suppurativa (HS).
COULD THIS STUDY BE RIGHT FOR YOU?
- Are at least 18 years old
- Were diagnosed with HS at least 6 months ago
- Haven’t seen enough improvement from a previous hidradenitis suppurativa (HS) treatment
WHAT PARTICIPANTS CAN EXPECT
If you qualify, you will have a random chance of receiving the investigational drug or placebo for 16 weeks, both administered as weekly subcutaneous (under the skin) injections. After this, all participants, including those initially assigned to receive the placebo, will receive the investigational drug either weekly or every other week. Overall, the study includes approximately 32 study visits. Those who successfully complete the study may be eligible to enroll in a separate long-term extension study to continue receiving the investigational drug.
IRB: SSU00263409A
- AbbVie - US - M20-465, A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa (Pro00078229)
MEET THE RESEARCHER
Joe K. Tung
Joe K. Tung, MD, MBA received his undergraduate degree in Molecular Biophysics and Biochemistry at Yale University and his medical degree at Harvard Medical School. He concurrently obtained his Master of Business Administration from Harvard Business School, graduating in the top 5% as a Baker Scholar. Dr. Tung went on to complete his internal medicine intern year at the Brigham and Women's Hospital and his dermatology residency at the University of Pittsburgh Medical Center.
Dr. Tung won a gold medal representing the United States at the 43rd International Chemistry Olympiad. His basic science and clinical research work have resulted in multiple peer-reviewed articles, reviews, textbook chapters, clinical decision support tools, and presentations at national and international meetings. He serves as a reviewer for research journals, as a consultant for pharmaceutical and biotechnology companies, as a principal investigator for global industry-sponsored clinical trials, and as an advisor for multiple healthcare start-ups. In his spare time, Dr. Tung enjoys traveling, playing golf, rock climbing, visiting museums, and attending live sporting events.